These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32733470)

  • 1. Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients.
    Valdés-Ferrada J; Muñoz-Durango N; Pérez-Sepulveda A; Muñiz S; Coronado-Arrázola I; Acevedo F; Soto JA; Bueno SM; Sánchez C; Kalergis AM
    Front Immunol; 2020; 11():1413. PubMed ID: 32733470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
    O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
    Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
    Litviakov N; Tsyganov M; Larionova I; Ibragimova M; Deryusheva I; Kazantseva P; Slonimskaya E; Frolova I; Choinzonov E; Cherdyntseva N; Kzhyshkowska J
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):99-109. PubMed ID: 29728799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HER2 CD4
    De La Cruz LM; McDonald ES; Mick R; Datta J; Nocera NF; Xu S; Fisher CS; Czerniecki BJ
    Ann Surg Oncol; 2017 Apr; 24(4):1057-1063. PubMed ID: 27826664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.
    Rivas M; Acevedo F; Dominguez F; Galindo H; Camus M; Oddo D; Villarroel A; Razmilic D; Peña J; Munoz Medel M; Navarro ME; Perez-Sepulveda A; Medina L; Merino T; Briones J; Kalergis A; Sanchez C
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2209-2212. PubMed ID: 31350986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
    Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
    Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
    Giro C; Yamada AMTD; Cruz FJSM; do R Barros LA; da C A Alves B; Fonseca FLA; Del Giglio A
    Breast Cancer Res Treat; 2024 Jul; 206(2):329-335. PubMed ID: 38743176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
    Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B
    Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
    Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
    J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
    Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
    Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
    You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
    Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery.
    Verma C; Kaewkangsadan V; Eremin JM; Cowley GP; Ilyas M; El-Sheemy MA; Eremin O
    J Transl Med; 2015 Jun; 13():180. PubMed ID: 26040463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.